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Abstract
Amino- and polyaminophthalazinones were synthesized by the palladium‐catalyzed amination (alkyl- and arylamines, polyamines)
of 4-bromophthalazinones in good yields. The coordinating properties of selected aminophthalazinones towards Cu(II) ions were
investigated and the participation of the nitrogen atoms in the complexation of the metal ion was shown. A biological screening of
the potential cytotoxicity of selected synthesized compounds on HT-29 and PC-3 cell lines, as well as on the L-929 cell line, proved
that some amino derivatives of phthalazinone show interesting anticancer activities. The detailed synthesis, spectroscopic data, and
biological assays are reported.
Introduction
Phthalazine and its analogs are an interesting group of pharma-
cologically active heterocycles [1,2], many of which possess,
e.g., antimicrobial [3,4], antifungal [5], antidepressant [6,7], and
antihistaminic [8-10] properties. Amino- and amidophthalazine
derivatives have been examined, e.g., as inhibitors of PGE2 pro-
duction [11] that plays an important role in the growth of
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Figure 1: Structure of biologically active phthalazine derivatives.
various cancerous tissues (colon, lung, and breast cancer) and as
antagonists of the human A3 adenosine receptor [12].
Aminophthalazines have been also evaluated for their inhibitory
activity toward phosphodiesterases such as PDE-5 (Figure 1)
[13,14] and PDE-10 [15] for a potential use in the treatment of
chronic pain and neurodegenerative or psychiatric disorders.
Some of these derivatives are known to possess anti-inflamma-
tory (p38 MAP kinase inhibitors, Figure 1) [16], cardiotonic
[17], and anticancer (Aurora-A kinase inhibitors) properties
[18-20].
The aminophthalazine and also hydrazinylphthalazine moiety
can be also found in the core of many commercial drugs such as
hydralazine [21-23], budralazine [24], and carbazeran [25] that
are used for the treatment of heart failure as well as in the struc-
ture of the effective anticancer drug vatalanib [26-28]
(Figure 1). On the other hand, aminophthalazinones can be
prospective candidates as N- and O-donor ligands to form com-
plexes with biological significant metal ions, such as copper or
zinc [29].
Recently, we have demonstrated a strategy for the synthesis of
phthalazinone and phthalazine derivatives of type 4 containing
an alkylsulfanyl functional group at the 4 position, that is based
on the Pd-catalyzed coupling reaction between mercaptanes and
4-bromolactams (Scheme 1, route A) [30]. In continuing our
efforts on the functionalization of phthalazinones and quinazoli-
nones [30,31] and taking into consideration the biological
importance of aminophthalazine derivatives, we decided to
apply the methodology based on the palladium-catalyzed C–N-
bond formation (Buchwald–Hartwig-type reaction) as a conve-
nient and effective approach for the synthesis of the new phtha-
lazinone derivatives 5 and 6 (Scheme 1, route B).
In the literature, the number of reported synthetic methods for
4-aminophthalazin-1(2H)-ones is limited to a few examples and
they usually involve two main approaches: 1) the application of
multicomponent reactions starting from, e.g., the available
o-bromobenzoate via palladium-catalyzed isocyanide insertion
[32,33] (a method that is limited to tertiary-substituted
isocyanides) or 2) the palladium or copper-catalyzed coupling
of bromolactams with amines (a method that requires the
usually lengthy synthesis of the bromoprecursors) [19,34].
Therefore, the need to develop new and improve the existing
methods for the synthesis of aminophthalazinones is important
from the point of view of their properties and pharmaceutical
industry interest.
In the present work, we report results of our research on
the synthesis, application as ligands in complexes, and cyto-
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Scheme 1: Synthetic route to aminophthalazinones 5 and 6.





The synthetic route toward the aminophthalazinones 5 and 6 is
shown in Scheme 1 (route B). A current literature review
[19,34] and our experience [35] proved, that the direct Pd-cou-
pling of bromophthalazinones of type 2 and also bromoquina-
zolinones, having an N–H moiety (acidic hydrogen atom) with
amines does not yield satisfying results without an N-protection
of the amide function.
Therefore, in the initial stage of our studies, the N-substituted
phthalazin-1(2H)-ones 3a–d were prepared in two steps starting
from phthalazin-1(2H)-one (1). The 4-bromo-derivative 2 was
synthesized directly from lactam 1, which underwent the selec-
tive bromination at the 4-position using the combination of Br2
and KBr (KBr3) in acetate buffer, following the method previ-
ously reported by us [30]. It is known that the alkylation of
phthalazinones depends on the reaction conditions and can
proceed in two ways involving either the nitrogen or the oxygen
atom (lactam–lactim tautomerism). It has been proven that
potassium salts of phthalazinones or the bromo derivatives are
selectively alkylated on the nitrogen atom [30,36]. For our
purposes, the simple alkyl halides (MeI, iPrI), and 2-chloro-
N,N-dimethylethylamine hydrochloride and 4-(2-chloro-
ethyl)morpholine hydrochloride, were chosen as the alkylating
agents. Thus, the desired N-methyl and N-isopropyl lactams
3a,b (3a R1 = Me, 85%; 3b R1 = iPr, 84%) were obtained by
the direct alkylation of bromophthalazinone 2 with methyl or
isopropyl iodide in the presence of K2CO3 in dry acetone as the
solvent (conventional heating). In the similar way also the
2-aminoethyl lactams 3c (R1 = CH2CH2NMe2) and 3d
(R1 = CH2CH2(morpholin-4-yl) were synthesized with 53% and
61% yields, respectively. The methodology turned out to be the
most efficient out of the tested ones, especially for the products
3c and 3d. The formation of the N-alkylated products 3 was
confirmed on the basis of their spectral analysis (see Support-
ing Information File 1).
In the next step, the bromolactams 3 were subjected to a ther-
mal palladium cross-coupling reaction with various amines and
polyamines. To optimize the reaction conditions, we investigat-
ed the reaction of 4-bromo-2-methylphthalazin-1(2H)-one (3a)
with morpholine as the model substrates. Previously, we have
observed that the coupling system involving Xantphos/
Pd(OAc)2 (used in the ratio of 15 mol %/15 mol % or
30 mol %/30 mol %) and t-BuOK or DIPEA in 1,4-dioxane as
the solvent was effective for the C–N or C–S bond formation
[30,31,35].
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Unfortunately, it turned out, that the application of Xantphos/
Pd(OAc)2/t-BuOK and our standard procedure [30,35], in
which the amine is added after the lactam 3a, for the initial ex-
periments ended with failure. In most cases, regardless of the
used catalytic system (Pd source: Pd(OAc)2, Pd2(dba)3, ligand:
DPEPhos, DavePhos, BINAP), solvent (1,4-dioxane, toluene)
and base (t-BuOK, DIPEA, Cs2CO3), the 1H NMR spectra of
the post-reaction mixtures indicated the presence of unchanged
substrate 3a. Also, the variation of the reactant quantities
(ligand/Pd source = 15:15, 23:15, 23:7.5, 20:20 mol %) and the
reaction time did not have a positive effect on the course of the
reaction and in several cases resulted in the formation of
2-methylphthalazin-1(2H)-one, i.e., the debromination product
of bromophthalazinone 3a.
The commonly adopted view on the mechanism of the Pd-medi-
ated C–N-bond formation (Buchwald–Hartwig-type coupling)
[37-40] assumes that the coordination of the amine takes place
after the oxidative addition of the organic halide to the palla-
dium–ligand complex. Based on the analysis of our results we
have concluded that in the case of systems 3, the order of
reagent addition could have a significant impact on a proper
course of the cross-coupling reaction. To confirm this idea, we
carried out an experiment in which to the in situ-generated
(BINAP)Pd complex (Pd2(dba)3/rac-BINAP or (R)-BINAP;
15:15 mol %) morpholine was added prior to the addition of
lactam 3a. As a result, we obtained the target 4-(morpholin-4-
yl) derivative 5a in 77% yield. Moreover, it turned out that this
amination reaction also proceeded with a reduced amount of
Pd2(dba)3 from 15 mol % to 2 mol % without loss of the prod-
uct yield.
These results showed that the coordination of the amine to the
(BINAP)Pd complex probably leads to the formation of a
(BINAP)Pd–amine system (Figure 2), facilitating the oxidative
addition of the bromolactam 3a and is the crucial step in the
amination procedure of 4-bromophthalazinones [40].
Based on the results of our initial studies, we next examined the
reaction scope of the bromolactams 3 with various amines and
polyamines. As can be seen from Scheme 2 the yields of the
amination products 5 and 6 were dependent on the nature of the
amine as well as on the used phthalazinone. Efficient results of
coupling were received using, inter alia, cyclic, aromatic or
benzylamines. The reaction of 3a with piperidine gave a higher
yield of the target product 5c (85%) compared to the use of
morpholine (5a, 77%), and especially thiomorpholine (5b,
62%). In turn, the use of 1-aminohexane (NH2Hex) in the reac-
tion with 3b resulted in a significant decrease in the yield of
product 5e (50%) in comparison with 2-(thiophen-2-yl)ethan-1-
amine (5f, 80%), cyclohexylamine (5d, 85%), and also with the
Figure 2: Proposed catalytic cycles for the amination of 4-bromophtha-
lazinones of type 3 (Phthal: phthalazinone, PhthalBr: 4-bromophtha-
lazinone, PhthalNR1R2: 4-aminophthalazinone).
4-CF3 and 4-OMe-benzylamines (5g, 85%; 5h, 65%). Addition-
ally, when using primary amines in the reaction the formation
of polysubstituted products was not observed.
On the other hand, N-phenylpyridin-2-amine afforded the
appropriate compound 5i in a lower yield as compared with ali-
phatic amines. Moreover, it turned out that an aminoalkyl sub-
stituent attached to the lactam scaffold did not disturb its func-
tionalization at the 4 position by a simple amine. The corre-
sponding product 5j was obtained in 89% yield.
It was found that also polyamines are suitable reagents in this
Pd-coupling reaction. Only the reaction of 3c with N1,N1-
diethylpentane-1,4-diamine proceeded in a lower yield and the
target derivative 6e was isolated with 44% yield. In the case of
N,N′-dimethylethylenediamine the substitution of both nitrogen
atoms was not observed. Instead, the partial demethylation of
the amine occurred. As a result, a mixture of the products 6c
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562
Scheme 2: Synthesis of 4-amino- and 4-polyaminophthalazinones 5 and 6 (the yields refer to the isolated compounds).
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and 6d (molar ratio 6c/6d = 1:4) was obtained. With the
increase in the amount of palladium (15 mol %) the phthalazin-
1(2H)-one derivative 6d was obtained as the main product
(70%).
Complexation behavior of aminophthalazinones with
Cu(II) ions
To conclude the synthetic research, we looked at the potential
of aminophthalazinones as polydentate ligands for the synthesis
of complexes with metal ions. Examples of the use of phthalazi-
none and its derivatives in the synthesis of coordination com-
pounds with La(III), Co(II), Cu(II), Mn(II) were extremely
interesting [41,42]. Despite the fact that the phthalazinone mol-
ecule is potentially a tridentate NNO ligand, so far, in the exam-
ples described in the literature the coordination takes place
through the oxygen atom [41,42]. Having synthesized
4-aminophthalazinones, we decided to investigate how these
compounds behave towards Cu(II) ions. For testing, we chose
the derivatives of ethylenediamine 6d, N-phenylpyridin-2-
amine 5i, and additionally the pyridin-2-yl derivative 7
(Figure 3). Compound 7 was synthesized according to the
method described by us [43].
Figure 3: The phthalazinone derivatives that were used to test the
complexation of Cu(II) ions.
All selected compounds (Figure 3) contain some specific struc-
tural elements (e.g., an ethylenediamine moiety, similarity to
bipyridyl or even to isocyclam skeleton) allowing them to act as
ligands and form complexes. In our tests, we hoped that putting
in the 4-position of the skeleton a substituent with a donor
nitrogen atom could result in the formation of complexes
following a different way of coordination with the metal ion
than described in the literature [41].
The complexing properties of compounds 5i, 6d, and 7 were in-
vestigated by mass spectrometry (ESIMS). The spectra were re-
corded after time intervals of 0 h, 1 h, and 24 h starting from
mixing the solutions containing equimolar amounts of the
ligand and CuCl2. Unexpectedly, compound 6d (L1) did not
show any complexing properties. In all spectra a signal of the
same ligand, despite long reaction times, was only observed
(ESIMS, negative ion mode, m/z = 231.1 Da; ESIMS, positive
ion mode, m/z = 233.1 Da (100%)).
In the case of compound 5i (L2), the formation of two types of
complexes was detected:  1)  with m /z  = 426.2 Da
[(L2)63Cu(II)Cl]+, 428.2 Da [(L2)65Cu(II)Cl]+ and 2) with
m/z = 719.5 Da and 721.5 Da, which corresponded to the
63Cu2+/65Cu2+ ion complex containing two ligands L2. Howev-
er, a significant amount of unchanged ligand was also visible.
For the ion at m/z = 719.5 Da, tandem spectra were recorded.
The first fragmentation gave ions at m/z = 329.3 Da (L2 + H+)
and 391.4 Da (ligand L2 and copper). The further fragmenta-
tion of the ion at m/z = 391.4 Da gave rise to an ion series:
362.4 Da (probably after elimination of HCO), 311.4 Da,
286.3 Da (100%), and 235.4 Da. We did not observe in the
tandem spectra the signal after the elimination of copper alone.
Similarly, the ESIMS spectrum of an equimolar mixture of
compound 7 (L3) and CuCl2 showed the presence of two types
of complexes containing one and two phthalazinone ligands:
[(L3)Cu(II)Cl]+ and [(L3)2Cu2(II)Cl3]+. The most abundant
peak at m/z = 422.3 Da corresponded to the complex
[(L3)Cu(II)Cl]+. The MS/MS fragmentation of the ions at
m/z = 422.3 Da for 63Cu and 424.3 Da for 65Cu followed the
same fragmentation pattern for both ions. The proposal of the
fragmentation pathway, based on the X-ray crystal structure of
the Cu(II) complex with 7 (L3) (Figure 4, vide infra), is shown
in Scheme 3. The MS/MS fragmentation analysis of the
[(L3)Cu(II)Cl]+ complex 8 (m/z = 422.3 and 424.3 Da) showed
at the first step the loss of an aminoalkyl fragment
(C2H3NMe2 = 71.1 Da) to form the ions 9 ⇌ 10 (m/z = 351.2
and 353.2 Da). Because of the lactam–lactim tautomerism the
further complex decomposition can proceed through two frag-
mentation routes: 1) with the loss of HCl/CO or 2) with the loss
of HCl/N2 (≈64 Da). In both cases, the pyridazinone moiety
undergoes degradation to different ions 11, 12 with the same
m/z = 287.3 and 289.3 Da. In the next stage, the copper cation is
detached to form ions 13 and 14 (224.3 Da) indicating that the
copper is well fitted into compound moiety.
Based on the results of X-ray structural analysis of the Cu(II)
complex with 7, it can be assumed, that also in the case of
ligand 5i (L2) the nitrogen atoms of the pyridin-2-yl and azome-
thin moiety participate in the coordination with Cu(II) ions.
Beilstein J. Org. Chem. 2021, 17, 558–568.
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Scheme 3: The proposal of the fragmentation pathway of the Cu(II)
complex with compound 7.
Crystallography of complex 17
The copper(II) complex 17 [(L3)Cu(II)Cl2] was synthesized and
characterized by X-ray analysis, FTIR and vis–NIR spectrosco-
py (for details see Supporting Information File 2). The molecu-
lar structure of the complex 17 is shown in Figure 4 and
Figure 5.
Figure 4: Structure of complex 17.
Figure 5: Molecular structure of complex 17 with atom numbering
scheme. The anisotropic displacement parameters are shown at the
50% probability level.
The basic experimental details and selected crystallographic
data are summarized in Table 1. For full details on the compari-
son of experimental and calculated bond lengths and bond
angles of complex 17 are provided in Supporting Information
File 2, Table S1. The complex 17 crystallizes in the monoclinic
Pc space group with two molecules A and B in one asymmetric
unit. Their geometry was fully optimized in vacuum using the
DFT method with the crystal structure coordinates as the input
geometry (optimized at the CAM-B3LYP/6–311++G(d,p)/
LanL2DZ(Cu) level of theory). However, due to the conver-
gence failure during the geometry optimization of the dimer of
molecules A and B, the geometry optimization was performed
for the isolated molecules A and B.
In a solid phase the Cu(II) central ion is five-coordinated by
three nitrogen atoms of 7 and two chloride anions. The
Beilstein J. Org. Chem. 2021, 17, 558–568.
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Table 1: Crystallographic data for complex 17.
















Dx (g cm−3) 1.620
μ (mm−1) 1.466
scan method Ω-scan
θ range (°) 2.9, 26.5
measured reflections 13642
unique reflections 5023
observed reflections [I>2σ(I)] 4548
completeness to θmax (%) 99.7
R [I>2σ(I)] 0.0408
wR (all data) 0.0943
S 1.04
largest diff. peak, hole (e Å−3) −0.45, 0.93
CuN3Cl2 coordination center adopts the strongly distorted
square pyramidal geometry with the five-coordinate geometry
index (τ5) of 0.45 and 0.42 for molecules A and B, respectively.
In particular, in molecules A and B, the pyridin-2-yl nitrogen
atoms (N3 and N5), the azomethine nitrogen atoms (N1 and
N7), and the tertiary nitrogen atom of the (2-(dimethyl-
amino)ethyl group (N4 and N6) act as donors of coordination
bonds. The coordination sphere of the Cu1 and Cu2 central ions
is completed with Cl1, Cl2 and Cl3, Cl4 chloride anions, re-
spectively. In the molecules A and B the pyridin-2-yl substitu-
ents are twisted in opposite directions relative to the mean plane
of the 1,2-diazine moiety with the dihedral angles equal to
27.61 and 28.71°, respectively, and moreover, the methyl
groups of the methoxy substituents are directed opposite and
towards to the pyridin-2-yl substituents, respectively. The
crystal structure of complex 17 is stabilized with a 3D intermo-
lecular hydrogen bond network (Figure S1a, Supporting Infor-
mation File 2). Additionally, the complex 17 in a solid state is
also stabilized with π–π stacking interactions between the 1,2-
diazine moieties and the pyridin-2-yl substituents of the ligands
(Figure S1b, Supporting Information File 2).
The FTIR spectrum recorded for complex 17 confirmed the
coordination of copper(II) through nitrogen atoms of the
pyridin-2-yl substituent, the pyridazin-3-one moiety, and the
2-(dimethylamino)ethyl group. In the vis–NIR spectrum
recorded in methanol, based on TD-DFT calculations, the
d–d, metal–ligand charge transfer (MLCT), ligand–metal
charge transfer (MLCT), and intraligand charge transfer
(ILCT) transitions were identified. The vis–NIR spectroscopy
revealed that in complex 17 the metal-to-ligand stoichiometry is
equal to 1:1. In turn, cyclic voltammetry was used to investi-
gate the electrochemical behavior of complex 17. The measure-
ments on a platinum disc electrode suggested that the
[(L3)Cu(II)Cl2]/[(L3)Cu(I)Cl2] redox couple was formed. For
more details, see Supporting Information File 2.
Bioactivity
Cytotoxicity analysis – MTT assay
We used the MTT assay to evaluate compounds 5c, 5d, 5f,
5g, 6b, and 6d for their potential activity on cytotoxicity,
proliferation and growth of HT-29 (human colon adenocarci-
noma cell line), PC-3 (human prostate cancer cell line) and
L-929 cells (mouse fibroblast cell line). The results obtained
from the MTT assay revealed that the tested phthalazinone de-
rivatives were cytotoxic towards the tested cell lines in the con-
centration range from 20.1 μM to 92.93 μM (Figure 6 and
Figure 7).
The compounds 5d, 5g and 5f exhibited the strongest cytotoxic
effects as compared to the other examined compounds. The
IC50 values for the tested cell lines were respectively: HT-29
(IC50 = 29.79 µM; 31.45 µM; 27.41 µM), PC-3 (IC50 =
20.12 µM; 22.4 µM; 27.27 µM) and L-929 (IC50 = 20.44 µM;
21.32 µM; 20.1µM). However, derivatives 6d and 5c appeared
to be less cytotoxic against all tested cell lines. The IC50 values
for the tested cell lines were respectively: HT-29 (IC50 =
75.58 µM; 36.67 µM), PC-3 (IC50 = 82.95 µM; 45.98 µM) and
L-929 (IC50 = 52.69 µM; 27.35 µM). Despite the fact that the
compounds were cytotoxic to tumor cell lines, they were also
similarly or even more cytotoxic to the control line (L-929),
which is not a desirable feature for any kind of a new potential
pharmaceutical drug.
Among the analyzed compounds only compound 6b significant-
ly influenced the viability of the tumor cell lines HT-29
(IC50 = 51.65 μM) and PC-3 (IC50 = 66.27 μM) compared to
normal cells L-929 (IC50 = 92.93 μM). However, in order to de-
termine further biological utility of compound 6b, additional
research has to be done,
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Figure 6: Determination of relative cell viability (% of control) in different cell lines (HT-29; PC-3 and L-929) treated with compounds 6d (1), 6b (2),
5d (3), 5c (4), 5g (5), 5f (6) using the MTT assay. The SEM value is shown for each tested concentration value.
Beilstein J. Org. Chem. 2021, 17, 558–568.
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Figure 7: Cytotoxic properties of the phthalazinone derivatives
expressed as IC50 after 72 h of cell treatment. Values significantly
differing from the control cell line (L-929) by ANOVA and Dunnett’s
test: * increase and # decrease.
Conclusion
In conclusion, we have demonstrated an efficient synthesis of
2-substituted (alkyl, aminoalkyl) 4-aminophthalazinones 5 and
6 via the direct bromination of phthalazin-1(2H)-one (1) with
potassium tribromide, followed by the alkylation of 4-bromo-
phthalazinone 2 with methyl iodide, isopropyl iodide or
2-chloro-N,N-dimethylethylamine and 4-(2-chloroethyl)mor-
pholine and further palladium-catalyzed amination of lactams 3
with aliphatic, aromatic, benzylic, cyclic amines and poly-
amines. Furthermore, we have demonstrated that some of the
phthalazinone derivatives act as ligands and form stable coordi-
nation compounds with Cu(II) ions. The results of biological
tests showed that the compounds containing an amino- or
polyamino-substituent at the 4-position of the phthalazinone
moiety could have potential applications as new anticancer
agents.
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